Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (43) clinical trials

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.

Phase

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

OBJECTIVES: Primary - Compare the tumor-specific immune response, in terms of the number of gp100-specific cytotoxic T-lymphocytes, T-cell production of interferon gamma, or T-cell proliferation in response to in vitro exposure to gp100 and tumor lysate, in patients with stage III or IV melanoma treated with autologous dendritic cells (DC) ...

Phase

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

This is a single-arm, multicenter study of vemurafenib in patients with biopsy-accessible advanced metastatic melanoma. The trial will consist of a screening period, a treatment phase, and one post-study follow-up visit occurring about 30 days after the last dose of drug. Day 1 of the study will be defined as ...

Phase

Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

This is a single arm, multi-center Phase II clinical trial to assess the safety and demonstrate the efficacy of a combined modality approach using radiation therapy after induction and concurrently with systemic administration of vismodegib, which may increase the rates of complete response and sustained local control in patients with ...

Phase

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Leptomeningeal Disease: (Cohort D): Study Visits: You are expected to stay in the Houston area for at least 21 days in order to take part in this study. During this study, you will have the following tests and procedures: - You will have an MRI of the complete spine and ...

Phase

Sorafenib Tamoxifen and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

OBJECTIVES: - Compare relapse-free and overall survival of patients with high-risk stage III melanoma receiving adjuvant sorafenib tosylate, tamoxifen citrate, and cisplatin vs historical data from patients treated with tamoxifen citrate and cisplatin. - Compare the toxicity of these regimens in these patients. OUTLINE: This is a pilot study. Patients ...

Phase

Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors

Background: cellular immunotherapy with dendritic cells (DC) loaded with tumor antigens has shown clinical activity, although in a small number of patients. Therefore, is is mandatory to improve the results of this strategy and to closely monitor immunologic response and cell migration in order to improve our understanding of mechanisms ...

Phase

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma Acral Melanoma or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

OBJECTIVES: Primary - To estimate the objective tumor response rate in patients with KIT-positive, unresectable, locally advanced or metastatic acral or mucosal melanoma treated with dasatinib monotherapy. Secondary - To estimate the response duration in patients treated with this drug. - To estimate the progression-free survival of patients treated with ...

Phase

Pentamidine in Treating Patients With Relapsed or Refractory Melanoma

OBJECTIVES: Primary - To determine the response rate in patients with relapsed or refractory melanoma that expresses wild-type p53 and S100B treated with pentamidine. Secondary - To observe the effect of this drug on the expression of S100B and p21 in tumor biopsy samples. - To observe the effect of ...

Phase

Chemotherapy and Total-Body Irradiation Followed By Laboratory-Treated Autologous Lymphocytes Aldesleukin and Vaccine Therapy in Treating Patients With Metastatic Melanoma

OBJECTIVES: Primary - Determine if the administration of anti-gp100:154-162 and anti-MART-1:27-35 T-cell receptor (TCR) gene-engineered peripheral blood lymphocytes (PBL), high-dose aldesleukin, and gp100:154-162 or MART-1:26-35(27L) peptide vaccination following a chemoradiation lymphodepleting preparative regimen results in complete clinical tumor regression in patients with metastatic melanoma (closed as of 09/21/09). - Determine ...

Phase